Ignite Creation Date:
2025-12-25 @ 1:14 AM
Ignite Modification Date:
2025-12-25 @ 11:24 PM
Study NCT ID:
NCT05130593
Status:
COMPLETED
Last Update Posted:
2023-11-18
First Post:
2021-10-06
Is NOT Gene Therapy:
False
Has Adverse Events:
True
Brief Title:
Pilot Study Evaluating the Acceptability and Absorption of the Bioactive Compounds of a Russian Tarragon Nutrasorb Bar
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'jennifer.rood@pbrc.edu', 'phone': '225-763-2524', 'title': 'Jennifer C Rood, PhD', 'organization': 'Pennington Biomedical Research Center'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'Test Day (up to 4 hours)', 'eventGroups': [{'id': 'EG000', 'title': 'Phase 1', 'description': 'Participants taste-tested a bar containing PMI-5011/Nutrasorb for acceptability. Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'Phase 2', 'description': 'Participants consumed a bar containing PMI-5011/Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'otherNumAtRisk': 10, 'deathsNumAtRisk': 10, 'otherNumAffected': 0, 'seriousNumAtRisk': 10, 'deathsNumAffected': 0, 'seriousNumAffected': 0}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Palatability of Bar', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase 1', 'description': 'Participants taste-tested a bar containing PMI-5011/Nutrasorb for acceptability. Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}], 'classes': [{'title': 'Visual Appearance', 'categories': [{'measurements': [{'value': '77.4', 'spread': '19.7', 'groupId': 'OG000'}]}]}, {'title': 'Smell', 'categories': [{'measurements': [{'value': '59.5', 'spread': '19.2', 'groupId': 'OG000'}]}]}, {'title': 'Taste', 'categories': [{'measurements': [{'value': '27.8', 'spread': '24.4', 'groupId': 'OG000'}]}]}, {'title': 'Texture', 'categories': [{'measurements': [{'value': '50.6', 'spread': '20.8', 'groupId': 'OG000'}]}]}, {'title': 'Aftertaste', 'categories': [{'measurements': [{'value': '56.5', 'spread': '31.4', 'groupId': 'OG000'}]}]}, {'title': 'Pleasantness', 'categories': [{'measurements': [{'value': '32.2', 'spread': '25.6', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Test Day (immediately after taste-testing the bar)', 'description': 'Participants were asked to rate the bar on a visual analog scale to indicate their impression of its visual appearance, smell, taste, texture, aftertaste, and overall pleasantness. The scale range for each attribute is 0-100 with higher scores equating to a better outcome.', 'unitOfMeasure': 'score on a scale', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only the participants in Phase 1 of the study participated in taste-testing of the bar for palatability. Participants from Phase 1 were not allowed to participate in Phase 2.'}, {'type': 'SECONDARY', 'title': 'Levels of Plasma BIoactive (DMC-2) Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase 2', 'description': 'Participants consumed a Nutrasorb bar and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}], 'classes': [{'title': '- 10 min', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.00', 'groupId': 'OG000'}]}]}, {'title': '0 min', 'categories': [{'measurements': [{'value': '0.05', 'spread': '0.00', 'groupId': 'OG000'}]}]}, {'title': '30 min', 'categories': [{'measurements': [{'value': '0.094', 'spread': '0.026', 'groupId': 'OG000'}]}]}, {'title': '60 min', 'categories': [{'measurements': [{'value': '0.076', 'spread': '0.022', 'groupId': 'OG000'}]}]}, {'title': '120 min', 'categories': [{'measurements': [{'value': '0.087', 'spread': '0.026', 'groupId': 'OG000'}]}]}, {'title': '180 min', 'categories': [{'measurements': [{'value': '0.074', 'spread': '0.013', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of DMC-2. Nutrasorb bar: 250 kcal bar containing 30 g of PMI-5011/Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'unitOfMeasure': 'ug/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only the participants in Phase 2 of the study had blood samples drawn for measurement of bioactive compounds (DMC-2). Participants from Phase 1 were not allowed to participate in Phase 2.'}, {'type': 'SECONDARY', 'title': 'Levels of Serum Glucose Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase 2', 'description': 'Participants consumed a Nutrasorb bar and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}], 'classes': [{'title': '-10 min', 'categories': [{'measurements': [{'value': '88', 'spread': '6.2', 'groupId': 'OG000'}]}]}, {'title': '0 min', 'categories': [{'measurements': [{'value': '89', 'spread': '5.5', 'groupId': 'OG000'}]}]}, {'title': '30 min', 'categories': [{'measurements': [{'value': '91', 'spread': '6.9', 'groupId': 'OG000'}]}]}, {'title': '60 min', 'categories': [{'measurements': [{'value': '91', 'spread': '5.5', 'groupId': 'OG000'}]}]}, {'title': '120 min', 'categories': [{'measurements': [{'value': '90', 'spread': '4.7', 'groupId': 'OG000'}]}]}, {'title': '180 min', 'categories': [{'measurements': [{'value': '89', 'spread': '5.1', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'unitOfMeasure': 'mg/dL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only the participants in Phase 2 of the study had blood samples drawn for measurement of serum glucose. Participants from Phase 1 were not allowed to participate in Phase 2.'}, {'type': 'SECONDARY', 'title': 'Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Phase 2', 'description': 'Participants consumed a Nutrasorb bar and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}], 'classes': [{'title': '-10 min', 'categories': [{'measurements': [{'value': '9.6', 'spread': '12.8', 'groupId': 'OG000'}]}]}, {'title': '0 min', 'categories': [{'measurements': [{'value': '10.4', 'spread': '13.9', 'groupId': 'OG000'}]}]}, {'title': '30 min', 'categories': [{'measurements': [{'value': '30.7', 'spread': '30.5', 'groupId': 'OG000'}]}]}, {'title': '60 min', 'categories': [{'measurements': [{'value': '25.8', 'spread': '31.4', 'groupId': 'OG000'}]}]}, {'title': '120 min', 'categories': [{'measurements': [{'value': '14.3', 'spread': '16.7', 'groupId': 'OG000'}]}]}, {'title': '180 min', 'categories': [{'measurements': [{'value': '7.2', 'spread': '6.4', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (insulin). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'unitOfMeasure': 'uIU/mL', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED', 'populationDescription': 'Only the participants in Phase 2 of the study had blood samples drawn for measurement of insulin. Participants from Phase 1 were not allowed to participate in Phase 2.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Phase 1', 'description': 'Participants taste-tested a bar containing PMI-5011/Nutrasorb for acceptability. Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}, {'id': 'FG001', 'title': 'Phase 2', 'description': 'Participants consumed a bar containing PMI-5011/Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '10'}, {'groupId': 'FG001', 'numSubjects': '10'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': 'Phase 1', 'description': 'Participants taste-tested a bar containing PMI-5011/Nutrasorb for acceptability. Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}, {'id': 'BG001', 'title': 'Phase 2', 'description': 'Participants consumed a bar containing PMI-5011/Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Categorical', 'classes': [{'categories': [{'title': '<=18 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Between 18 and 65 years', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}, {'title': '>=65 years', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '11', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '4', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '9', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '1', 'groupId': 'BG001'}, {'value': '1', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '19', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Race (NIH/OMB)', 'classes': [{'categories': [{'title': 'American Indian or Alaska Native', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Asian', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Native Hawaiian or Other Pacific Islander', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Black or African American', 'measurements': [{'value': '3', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '3', 'groupId': 'BG002'}]}, {'title': 'White', 'measurements': [{'value': '7', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '17', 'groupId': 'BG002'}]}, {'title': 'More than one race', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'United States', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '20', 'groupId': 'BG002'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2020-05-14', 'size': 246754, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2022-11-01T15:33', 'hasProtocol': True}, {'date': '2020-05-14', 'size': 242158, 'label': 'Informed Consent Form', 'hasIcf': True, 'hasSap': False, 'filename': 'ICF_001.pdf', 'typeAbbrev': 'ICF', 'uploadDate': '2022-11-01T15:34', 'hasProtocol': False}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 20}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2021-10-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2023-11', 'completionDateStruct': {'date': '2022-10-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2023-11-14', 'studyFirstSubmitDate': '2021-10-06', 'resultsFirstSubmitDate': '2023-10-24', 'studyFirstSubmitQcDate': '2021-11-10', 'lastUpdatePostDateStruct': {'date': '2023-11-18', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2023-11-14', 'studyFirstPostDateStruct': {'date': '2021-11-23', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2023-11-18', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2022-10-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Palatability of Bar', 'timeFrame': 'Test Day (immediately after taste-testing the bar)', 'description': 'Participants were asked to rate the bar on a visual analog scale to indicate their impression of its visual appearance, smell, taste, texture, aftertaste, and overall pleasantness. The scale range for each attribute is 0-100 with higher scores equating to a better outcome.'}], 'secondaryOutcomes': [{'measure': 'Levels of Plasma BIoactive (DMC-2) Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of DMC-2. Nutrasorb bar: 250 kcal bar containing 30 g of PMI-5011/Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}, {'measure': 'Levels of Serum Glucose Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (glucose). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}, {'measure': 'Measurement of Blood Levels of Serum Insulin Before and After Ingestion of a Bar Containing PMI-5011/Nutrasorb.', 'timeFrame': '10 minutes pre-consumption, immediately post-consumption, and 30, 60, 120, and 180 minutes post-consumption', 'description': 'Participants consumed a bar containing PMI-5011 and Nutrasorb and had blood samples drawn for measurement of safety parameters (insulin). Nutrasorb bar: 250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['tarragon'], 'conditions': ['Diabetes Prevention']}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to make a bar from the soy-protein Russian Tarragon complex (PMI-5011/Nutrasorb) that is safe and acceptable for consumption, and to test the blood levels of plasma bioactive (DMC-2) after ingestion of the bar. The PMI-5011/Nutrasorb comes from a plant source called Artemisia dracunculus. This plant has a long history of medicinal (health) and culinary (food) use and has been reported as effective as a traditional treatment for diabetes in various parts of the world.', 'detailedDescription': "Phase 1\n\nTest Day: Fasting Visit (nothing to eat or drink other than water beginning at 10 pm the night before the test day); visit will be approximately 1 ½ hours.\n\nThe following procedures will be done on the Test Day:\n\n* Informed consent will be signed by those agreeing to participate.\n* Body weight and height will be measured (body mass index will be calculated from these measures).\n* Participants will provide a list of any medications they are currently taking.\n* Blood pressure and pulse will be measured.\n* Taste test of the study bar will be conducted.\n* Participants will answer questions regarding the appearance, smell, taste, texture, aftertaste, and pleasantness of the bar.\n\nPhase 1 participants may be asked to return up to two additional times to complete the taste test and questions again. This will occur if the product is found unacceptable and will be completed after a new bar is produced.\n\nPhase 2\n\nScreening Visit: Fasting Visit (nothing to eat or drink other than water after 10 pm the night before the Screening Visit); visit will be approximately 1 ½ hours.\n\nThe following procedures will be done on the Screening Visit:\n\n* Informed consent will be signed by those agreeing to participate.\n* Body weight and height will be measured (body mass index will be calculated from these measures).\n* Blood pressure and pulse will be measured.\n* Medical history questionnaire will be completed.\n* Blood will be drawn (approximately 2 teaspoons) to assess overall health.\n\nTest Day: Fasting visit (nothing to eat or drink other than water after 10 pm the night before the Test Day); visit will be approximately 4 hours and will be completed within 30 days after Screening Visit.\n\nThe following procedures will be done on the Test Day:\n\n* Blood will be drawn from an IV line placed in the participant's arm to assess the level of nutrients, blood sugar levels, and insulin levels from the study bar 10 minutes before the bar is consumed, immediately after the bar is consumed, and 30, 60, 120, and 180 minutes after the bar is consumed. A total of approximately 6 teaspoons of blood will be drawn for this Test Day.\n* Participants will answer questions regarding the appearance, smell, taste, texture, aftertaste, and pleasantness of the bar.\n* Participants will be asked about any side effects and how they feel throughout the Test Day."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT'], 'maximumAge': '50 Years', 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'healthy males and females aged 18-50 with a body mass index between 20-30 kg/m2', 'healthyVolunteers': True, 'eligibilityCriteria': "Inclusion Criteria:\n\n* Healthy males or females between 18 and 50 years of age inclusive.\n* Body mass index between 20-30 kg/m2.\n\nExclusion Criteria:\n\n* Pregnant or currently lactating.\n* Taking any prescription medications.\n* Taking any over-the-counter medications that cannot be stopped for test days.\n* Allergic to any ingredients contained in the bar.\n* Other conditions or situations that would interfere with the study or the participant's safety as determined by the investigators.\n* Participants in Phase 1 of the study may not participate in Phase 2 of the study."}, 'identificationModule': {'nctId': 'NCT05130593', 'briefTitle': 'Pilot Study Evaluating the Acceptability and Absorption of the Bioactive Compounds of a Russian Tarragon Nutrasorb Bar', 'organization': {'class': 'OTHER', 'fullName': 'Pennington Biomedical Research Center'}, 'officialTitle': 'Pilot Study Evaluating the Hedonic Acceptability and Absorption of the Bioactive Compounds of a 5011-Nutrasorb Bar (Russian Tarragon Nutrasorb)', 'orgStudyIdInfo': {'id': 'PBRC 2020-022'}, 'secondaryIdInfos': [{'id': '5P50AT002776-15', 'link': 'https://reporter.nih.gov/quickSearch/5P50AT002776-15', 'type': 'NIH'}]}, 'armsInterventionsModule': {'armGroups': [{'label': 'Nutrasorb bar evaluation', 'description': 'Participants in Phase 1 will taste test the bar for acceptability. Participants in Phase 2 will consume the bar and have blood samples drawn for measurement of safety parameters (glucose and insulin) and bioactive compounds (DMC-2).', 'interventionNames': ['Dietary Supplement: Nutrasorb bar']}], 'interventions': [{'name': 'Nutrasorb bar', 'type': 'DIETARY_SUPPLEMENT', 'description': '250 kcal bar containing 30 g of 5011-Nutrasorb (120 kcal), 20 g fat (100 kcal), and 30 kcal from carbohydrate and flavorings', 'armGroupLabels': ['Nutrasorb bar evaluation']}]}, 'contactsLocationsModule': {'locations': [{'zip': '70808', 'city': 'Baton Rouge', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Pennington Biomedical Research Center', 'geoPoint': {'lat': 30.44332, 'lon': -91.18747}}], 'overallOfficials': [{'name': 'Jennifer C Rood, Ph.D.', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Pennington Biomedical Research Center'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pennington Biomedical Research Center', 'class': 'OTHER'}, 'collaborators': [{'name': 'National Center for Complementary and Integrative Health (NCCIH)', 'class': 'NIH'}, {'name': 'Office of Dietary Supplements (ODS)', 'class': 'NIH'}], 'responsibleParty': {'type': 'PRINCIPAL_INVESTIGATOR', 'investigatorTitle': 'Principal Investigator', 'investigatorFullName': 'Jennifer C. Rood', 'investigatorAffiliation': 'Pennington Biomedical Research Center'}}}}